Navin Fluorine Q1 FY27: Growth accelerates as HPP, Specialty and CDMO scale up

Navin Fluorine International Limited opened FY27 with a sharp step-up in performance. In Q1 FY27, consolidated net revenue from operations rose to Rs. 1,045.08 crore, up 44 percent year on year and 11 percent quarter on quarter. Profitability improved even faster. Operating EBITDA climbed to Rs. 357.07 crore, up 73 percent year on year, and operating profit before tax increased to Rs. 283.27 crore, up 101 percent year on year. Profit after tax reached Rs. 243.31 crore, more than doubling from the year-ago quarter.

The quarter showed a consistent pattern that investors typically look for in specialty chemical and fluorination platforms: growth led by capacity and demand, coupled with operating leverage. Operating EBITDA margin stayed elevated at 34.2 percent, versus 28.5 percent in Q1 FY26. On a full-year basis, FY26 consolidated margin already improved to 32.6 percent from 22.7 percent in FY25, and Q1 FY27 sustained that higher band.

Segment performance: broad-based momentum across all three verticals

The company’s three business verticals contributed to growth, with the fastest expansion coming from the CDMO business.

High Performance Products (HPP) reported Q1 FY27 revenue of Rs. 540 crore compared with Rs. 407 crore in Q1 FY26, a 33 percent rise. The company attributed this to volume growth and higher realizations, and noted that the pricing environment for hydrofluorocarbons remains constructive. It also pointed to increasing interest for contractual offtakes in new capacities.

Specialty Chemicals delivered Q1 FY27 revenue of Rs. 325 crore versus Rs. 219 crore in Q1 FY26, growing 48 percent. Management highlighted strong order visibility, continued scale-up in existing molecules and a line-up of new launches. Two operating milestones remain important for this vertical: the Chemours project targeted for completion by end of Q2 FY27, and de-bottlenecking multi-purpose plant capacity at Dahej targeted for commissioning in Q3 FY27.

CDMO posted Q1 FY27 revenue of Rs. 180 crore against Rs. 99 crore in Q1 FY26, rising 82 percent. The presentation attributes this to a strong order book and deeper engagement with a European CDMO major, including increasing demand for an existing molecule and an expanding footprint in that partner’s supply chain. The company also reiterated its portfolio approach, balancing late stage and early stage molecules and increasing exposure to therapeutic areas including oncology, respiratory, cardiovascular, neurology and animal health.

Financial summary (consolidated)

Capex pipeline: linking expansion to commissioning timelines

A key part of the current investor narrative is not just the quarter’s growth but the visibility on future capacity and new vertical incubation. The company disclosed multiple projects with defined capex amounts and timelines.

In High Performance Products, Navin Fluorine is executing an additional hydrofluorocarbon capacity expansion equivalent upto 15,000 metric tonnes per annum of R32. The capex is Rs. 236.5 crore and is expected to be commissioned by Q3 FY27. The company indicates a peak revenue potential of about Rs. 600 to 825 crore per annum for this project. The stated rationale is a constructive global demand supply environment driven by the transition to low global warming potential gases, along with increasing refrigeration and air conditioning and blends demand in both India and export markets.

In Specialty Chemicals, de-bottlenecking of multi-purpose plant capacity at Dahej is planned with capex of Rs. 75 crore, targeted for commissioning by Q3 FY27. The company states it is to support the launch of a new molecule for a global innovator and notes that a purchase order has been received for calendar year 2026. Peak revenue potential is indicated at about Rs. 140 to 160 crore per annum.

In CDMO, the board had earlier approved cGMP4 capex of Rs. 288 crore in February 2024. Phase I was operationalized in Q3 FY26. The company has now initiated Phase II capex of Rs. 125 crore, expected to operationalize by Q4 FY27. Importantly, it provides a return proxy by stating an asset turnover of around 3 times.

Separately, the company is incubating an Advanced Materials vertical positioned around niche, high growth applications in data centers, electronics, defence and semiconductors. Two specific capex items are outlined. First is an Advanced Materials adoption capacity capex of Rs. 90 crore, intended to commercialise the product pipeline and enable commercial scale qualification supplies, with completion by Q2 FY28. Second is the Chemours project with capex of Rs. 120 crore, to set up initial commercial capacity enabling adoption of an innovative liquid cooling product, targeted for commissioning by Q2 FY27. A notable feature of this project is funding support, with 35 percent funded by the customer.

Sustainability and governance: clear framework, mixed operational progress

Navin Fluorine’s presentation lays out an ESG framework guided by Responsible Care and the Pharmaceutical Supply Chain Initiative. It also lists environmental targets such as 30 percent reduction in carbon emissions by 2030 from a 2023 base year and 50 percent use of renewable electricity by 2030.

Progress indicators in FY 2025-26 show a mixed picture. The company reports 100 percent compliance with extended producer responsibility requirements for plastic packaging. Renewable electricity usage was 12.15 percent in 2026. However, specific carbon emissions increased by 11.1 percent in CO2 per tonne of production. On the social and governance side, workplace diversity was 3.94 percent and gender diversity in leadership teams was reported at 0 percent in 2026. Complaint resolution stood at 89.24 percent versus a stated goal of 100 percent resolution.

The company also disclosed an investment of Rs. 15.73 crore in a special purpose vehicle for setting up a hybrid power plant, covering 14.9 megawatts of hybrid capacity across NFIL and NFASL. It states this will lead to over 60 percent of energy needs met from renewable sources.

Takeaways for investors

Q1 FY27 reinforces that Navin Fluorine is in a phase where growth and margins are scaling together, supported by strong contributions from all three verticals and especially rapid expansion in CDMO. The more durable part of the story is the clearly articulated capex roadmap with commissioning timelines across HPP, Specialty Chemicals, CDMO and the emerging Advanced Materials vertical.

Over the next few quarters, investor focus is likely to stay on execution against the stated commissioning milestones: HFC and MPP in Q3 FY27, Chemours in Q2 FY27, and cGMP4 Phase II in Q4 FY27. Alongside this, sustainability metrics and governance process outcomes, such as carbon intensity trajectory, renewable adoption levels and complaint resolution, remain visible areas where the company has set goals and provided baseline progress data.